Latest & greatest articles for opioid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on opioid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on opioid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for opioid

161. Prior Opioid Use Does Not Impact the Response to Pregabalin in Patients With Fibromyalgia

Prior Opioid Use Does Not Impact the Response to Pregabalin in Patients With Fibromyalgia 25756560 2016 06 09 2017 03 24 2017 03 24 1536-5409 32 7 2016 07 The Clinical journal of pain Clin J Pain Prior Opioid Use Does Not Impact the Response to Pregabalin in Patients With Fibromyalgia. 555-61 10.1097/AJP.0000000000000232 Fibromyalgia (FM) is a chronic pain disorder for which pregabalin is an approved treatment in the United States. Although opioids are not a recommended treatment option (...) , they continue to be used by many FM patients. The impact of patients' prior opioid use on their subsequent response to pregabalin has not been assessed. This was a pooled analysis of 4 clinical trials to assess the efficacy of pregabalin in FM patients both with and without prior opioid use. Patients were divided into those using opioids prior to the trial and those who were not. The change in least squares mean pain score (assessed by 0 to 10 numeric rating scale) with pregabalin compared with placebo

EvidenceUpdates2016

162. Opioids for restless legs syndrome.

Opioids for restless legs syndrome. BACKGROUND: Restless legs syndrome (RLS) is a distressing and common neurological disorder that may have a huge impact in the quality of life of those with frequent and intense symptoms. Patients complain of unpleasant sensations in the legs, at or before bedtime, and feel an urge to move the legs, which improves with movement, such as walking. Symptoms start with the patient at rest (e.g. sitting or lying down), and follow a circadian pattern, increasing (...) during the evening or at night. Many pharmacological intervention are available for RLS, including drugs used to treat Parkinson's disease (L-Dopa and dopaminergic agonists), epilepsy (anticonvulsants), anxiety (benzodiazepines), and pain (opioids). Dopaminergic drugs are those most frequently used for treatment of RLS, but some patients do not respond effectively and require other medication. Opioids, a class of medications used to treat severe pain, seem to be effective in treating RLS symptoms

Cochrane2016

163. Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain.

Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain. BACKGROUND: Unintentional overdose involving opioid analgesics is a leading cause of injury-related death in the United States. OBJECTIVE: To evaluate the feasibility and effect of implementing naloxone prescription to patients prescribed opioids for chronic pain. DESIGN: 2-year nonrandomized intervention study. SETTING: 6 safety-net primary care clinics in San (...) Francisco, California. PARTICIPANTS: 1985 adults receiving long-term opioid therapy for pain. INTERVENTION: Providers and clinic staff were trained and supported in naloxone prescribing. MEASUREMENTS: Outcomes were proportion of patients prescribed naloxone, opioid-related emergency department (ED) visits, and prescribed opioid dose based on chart review. RESULTS: 38.2% of 1985 patients receiving long-term opioids were prescribed naloxone. Patients prescribed higher doses of opioids and with an opioid

Annals of Internal Medicine2016

164. State Legal Restrictions and Prescription-Opioid Use among Disabled Adults.

State Legal Restrictions and Prescription-Opioid Use among Disabled Adults. BACKGROUND: In response to rising rates of opioid abuse and overdose, U.S. states enacted laws to restrict the prescribing and dispensing of controlled substances. The effect of these laws on opioid use is unclear. METHODS: We tested associations between prescription-opioid receipt and state controlled-substances laws. Using Medicare administrative data for fee-for-service disabled beneficiaries 21 to 64 years of age (...) who were alive throughout the calendar year (8.7 million person-years from 2006 through 2012) and an original data set of laws (e.g., prescription-drug monitoring programs), we examined the annual prevalence of beneficiaries with four or more opioid prescribers, prescriptions yielding a daily morphine-equivalent dose (MED) of more than 120 mg, and treatment for nonfatal prescription-opioid overdose. We estimated how opioid outcomes varied according to eight types of laws. RESULTS: From 2006

NEJM2016

165. Naloxone single dose nasal spray for opioid overdose

Naloxone single dose nasal spray for opioid overdose Naloxone single dose nasal spray for opioid overdose Naloxone single dose nasal spray for opioid overdose NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Naloxone single dose nasal spray for opioid overdose. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning (...) Review. 2016 Authors' conclusions Opioids are a type of drug that are used to treat pain but they may also be misused as they are highly addictive and lead to temporary feelings of intense pleasure. Addiction to opioids can develop very quickly, even when taken in small amounts. Treatment for opioid addiction can involve addicts being given carefully prescribed alternative drugs to reduce withdrawal symptoms and cravings. People who take opioids are at risk of overdose, which can lead to death

Health Technology Assessment (HTA) Database.2016

166. CAM2038 for opioid dependence

CAM2038 for opioid dependence CAM2038 for opioid dependence CAM2038 for opioid dependence NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. CAM2038 for opioid dependence. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Opioids are a type of drug used to treat pain (...) , but they may also be misused as they are highly addictive and lead to temporary feelings of intense pleasure (euphoria). Addiction to opioids can develop very quickly, even when taken in small amounts. Treatment for opioid addiction can involve addicts being given carefully prescribed alternative drugs to reduce withdrawal symptoms and cravings, without causing euphoria. CAM2038 is a new drug for the treatment of opioid dependence given as an injection under the skin once a week or once a month depending

Health Technology Assessment (HTA) Database.2016

168. The Effect of Dexmedetomidine on Postoperative Opioid Consumption and Pain After Major Spine Surgery

The Effect of Dexmedetomidine on Postoperative Opioid Consumption and Pain After Major Spine Surgery 27003917 2016 04 22 2016 09 07 2016 04 22 1526-7598 122 5 2016 May Anesthesia and analgesia Anesth. Analg. The Effect of Dexmedetomidine on Postoperative Opioid Consumption and Pain After Major Spine Surgery. 1646-53 10.1213/ANE.0000000000001226 Adult deformity correction spine surgery can be associated with significant perioperative pain because of inflammatory, muscular, neuropathic (...) , and postsurgical pain. α-2 Agonists have intrinsic antinociceptive and antihyperalgesic properties that can potentially reduce both postoperative opioid consumption and pain. We hypothesized that intraoperative dexmedetomidine would reduce postoperative opioid consumption and improve pain scores in deformity correction spine surgery. Patients undergoing >3 levels of thoracic and/or lumbar spine surgery were enrolled in this prospective randomized double-blind study to receive either dexmedetomidine (1 μg/kg

EvidenceUpdates2016

169. Development and preliminary validation of the Opioid Abuse Risk Screener

Development and preliminary validation of the Opioid Abuse Risk Screener 28070401 2018 11 13 2055-1029 3 1 2016 Jan Health psychology open Health Psychol Open Development and preliminary validation of the Opioid Abuse Risk Screener. 2055102916648995 10.1177/2055102916648995 Prescription opioid drug abuse has reached epidemic proportions. Individuals with chronic pain represent a large population at considerable risk of abusing opioids. The Opioid Abuse Risk Screener was developed (...) as a comprehensive self-administered measure of potential risk that includes a wide range of critical elements noted in the literature to be relevant to opioid risk. The creation, refinement, and preliminary modeling of the item pool, establishment of preliminary concurrent validity, and the determination of the factor structure are presented. The initial development and validation of the Opioid Abuse Risk Screener shows promise for effective risk stratification. Henrie-Barrus Patricia P The University of Utah

Health psychology open2016 Full Text: Link to full Text with Trip Pro

170. Is There a Benefit for Liposomal Bupivacaine Compared to a Traditional Periarticular Injection in Total Knee Arthroplasty Patients With a History of Chronic Opioid Use?

Is There a Benefit for Liposomal Bupivacaine Compared to a Traditional Periarticular Injection in Total Knee Arthroplasty Patients With a History of Chronic Opioid Use? 26897490 2016 07 25 2016 07 25 1532-8406 31 8 2016 Aug The Journal of arthroplasty J Arthroplasty Is There a Benefit for Liposomal Bupivacaine Compared to a Traditional Periarticular Injection in Total Knee Arthroplasty Patients With a History of Chronic Opioid Use? 1702-5 10.1016/j.arth.2016.01.037 S0883-5403(16)00099-1 (...) Postoperative pain after total knee arthroplasty (TKA) poses a major challenge. It delays mobilization, increases opioid consumption and side effects, and lengthens hospitalization. This challenge multiplies when treating an opioid-dependent population. We examined whether a novel suspended release local anesthetic, liposomal bupivacaine (LB) would improve pain control and decrease opioid consumption after TKA compared to a standard periarticular injection in opioid-dependent patients. Thirty-eight patients

EvidenceUpdates2016

171. Opioids Prescribed After Low-Risk Surgical Procedures in the United States, 2004–2012

Opioids Prescribed After Low-Risk Surgical Procedures in the United States, 2004–2012 26978756 2016 05 01 2018 11 13 1538-3598 315 15 2016 Apr 19 JAMA JAMA Opioids Prescribed After Low-Risk Surgical Procedures in the United States, 2004-2012. 1654-7 10.1001/jama.2016.0130 Wunsch Hannah H Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Wijeysundera Duminda N DN Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada (...) . Passarella Molly A MA Center for Outcomes Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Neuman Mark D MD Department of Anesthesiology and Critical Care, Perelman School of Medicine at the University of Pennsylvania, Philadelphia. eng K08 AG043548 AG NIA NIH HHS United States Canadian Institutes of Health Research Canada Journal Article Research Support, Non-U.S. Gov't United States JAMA 7501160 0098-7484 0 Analgesics, Opioid 362O9ITL9D Acetaminophen 6YKS4Y3WQ7 Hydrocodone

JAMA2016 Full Text: Link to full Text with Trip Pro

172. Opioid Prescribing After Surgical Extraction of Teeth in Medicaid Patients, 2000–2010

Opioid Prescribing After Surgical Extraction of Teeth in Medicaid Patients, 2000–2010 26978601 2016 05 01 2018 11 13 1538-3598 315 15 2016 Apr 19 JAMA JAMA Opioid Prescribing After Surgical Extraction of Teeth in Medicaid Patients, 2000-2010. 1653-4 10.1001/jama.2015.19058 Baker James A JA Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts. Avorn Jerry J Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's (...) Hospital, Boston, Massachusetts. Levin Raisa R Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts. Bateman Brian T BT Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts. eng K08 HD075831 HD NICHD NIH HHS United States K08HD075831 HD NICHD NIH HHS United States Journal Article Research Support, N.I.H., Extramural United States JAMA 7501160 0098-7484 0 Analgesics, Opioid AIM IM Adolescent

JAMA2016 Full Text: Link to full Text with Trip Pro

173. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. BACKGROUND: Extended-release naltrexone, a sustained-release monthly injectable formulation of the full mu-opioid receptor antagonist, is effective for the prevention of relapse to opioid dependence. Data supporting its effectiveness in U.S. criminal justice populations are limited. METHODS: In this five-site, open-label, randomized trial, we compared a 24-week course of extended-release naltrexone (Vivitrol (...) ) with usual treatment, consisting of brief counseling and referrals for community treatment programs, for the prevention of opioid relapse among adult criminal justice offenders (i.e., persons involved in the U.S. criminal justice system) who had a history of opioid dependence and a preference for opioid-free rather than opioid maintenance treatments and who were abstinent from opioids at the time of randomization. The primary outcome was the time to an opioid-relapse event, which was defined as 10

NEJM2016

174. Opioid Abuse in Chronic Pain - Misconceptions and Mitigation Strategies.

Opioid Abuse in Chronic Pain - Misconceptions and Mitigation Strategies. Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27028915 Format (...) MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Mar 31;374(13):1253-63. doi: 10.1056/NEJMra1507771. Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies. 1 , 1 . 1 From the National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD (N.D.V.); and the Treatment Research Institute, Philadelphia

NEJM2016

175. Nonmedical Prescription-Opioid Use and Heroin Use.

Nonmedical Prescription-Opioid Use and Heroin Use. Nonmedical Prescription-Opioid Use and Heroin Use. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27028930 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Mar 31;374(13):1296. doi: 10.1056/NEJMc1601875. Nonmedical Prescription-Opioid Use and Heroin Use. , , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27028930 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substance Full Text Sources Medical PubMed Commons 0 comments How to cite

NEJM2016

176. Nonmedical Prescription-Opioid Use and Heroin Use.

Nonmedical Prescription-Opioid Use and Heroin Use. Nonmedical Prescription-Opioid Use and Heroin Use. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27028931 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Mar 31;374(13):1295-6. doi: 10.1056/NEJMc1601875#SA1. Nonmedical Prescription-Opioid Use and Heroin Use. 1 , 1 . 1 Washington University School of Medicine in St. Louis, St. Louis, MO cicerot@wustl.edu. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27028931 DOI: [Indexed for MEDLINE] Publication types

NEJM2016 Full Text: Link to full Text with Trip Pro

177. Reducing the Risks of Relief - The CDC Opioid-Prescribing Guideline.

Reducing the Risks of Relief - The CDC Opioid-Prescribing Guideline. Reducing the Risks of Relief--The CDC Opioid-Prescribing Guideline. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26977701 Format MeSH (...) and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Apr 21;374(16):1501-4. doi: 10.1056/NEJMp1515917. Epub 2016 Mar 15. Reducing the Risks of Relief--The CDC Opioid-Prescribing Guideline. 1 , 1 . 1 From the Centers for Disease Control and Prevention, Atlanta. Comment on [MMWR Recomm Rep. 2016] PMID: 26977701 PMCID: DOI: [Indexed for MEDLINE

NEJM2016

178. Metered Pump Aerosolizing Devices for Opioid Administration: Clinical Effectiveness and Guidelines

Metered Pump Aerosolizing Devices for Opioid Administration: Clinical Effectiveness and Guidelines Metered Pump Aerosolizing Devices for Opioid Administration: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Metered Pump Aerosolizing Devices for Opioid Administration: Clinical Effectiveness and Guidelines Metered Pump Aerosolizing Devices for Opioid Administration: Clinical Effectiveness and Guidelines Published on: March 1, 2016 Project Number: RA0833-000 Product (...) Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of metered pump aerosolizing devices for the administration of opioids for pain or dyspnea relief? What are the evidence-based guidelines for the use of metered pump aerosolizing devices for the administration of opioids for pain or dyspnea relief? Key Message No relevant studies or guidelines were identified regarding the use of metered pump aerosolizing devices

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

179. How effective are opioids for chronic low back pain?

How effective are opioids for chronic low back pain? How effective are opioids for chronic low back pain? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics How effective are opioids for chronic low back pain? View/ Open Date 2015-09 Format Metadata Abstract Q: How effective are opioids for chronic low back pain? Evidence (...) -based answer: Short-term (<4 months) treatment with opioids provides modest relief of chronic low back pain, but only minimal improvement in function compared with placebo (strength of recommendation [SOR]: B, systematic review of lower-quality randomized controlled trials [RCTs]). Tramadol isn’t superior to nonsteroidal anti-inflammatory drugs (NSAIDs) for pain relief (SOR: A, consistent results from RCTs). In addition, oxycodone with titrated morphine isn’t better than naproxen for relieving pain

Clinical Inquiries2016

180. Rapid and Ultra-Rapid Detoxification in Adults with Opioid Addiction: A Review of Clinical- and Cost-Effectiveness, Safety, and Guidelines

Rapid and Ultra-Rapid Detoxification in Adults with Opioid Addiction: A Review of Clinical- and Cost-Effectiveness, Safety, and Guidelines Rapid and Ultra-Rapid Detoxification in Adults with Opioid Addiction: A Review of Clinical- and Cost-Effectiveness, Safety, and Guidelines | CADTH.ca Find the information you need Rapid and Ultra-Rapid Detoxification in Adults with Opioid Addiction: A Review of Clinical- and Cost-Effectiveness, Safety, and Guidelines Rapid and Ultra-Rapid Detoxification (...) in Adults with Opioid Addiction: A Review of Clinical- and Cost-Effectiveness, Safety, and Guidelines Published on: January 15, 2016 Project Number: RC0742-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of rapid and ultra-rapid opioid detoxification (ROD and UROD) in adults with opioid addiction? What is the cost-effectiveness of ROD and UROD in adults with opioid addiction? What

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016